BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Buckinghamshire Clinical Commissioning Group (CCG) would like to invite you to a stakeholder meeting to discuss the future provision of anticoagulant services across Buckinghamshire.
The existing warfarin monitoring service contract provided under an AQP arrangement ends on the 31st March 2020. This gives the CCG an opportunity to review the current anticoagulation monitoring arrangements that will include the use of warfarin, Direct Oral Anticoagulants (DOACs) and dalteparin.
The aim is to re-commission an anticoagulation service that is equitable across Buckinghamshire whilst providing assurance that patient outcomes and safety are maximised.
This initial stakeholder meeting is to gain your views and thoughts on what this new service should look like.
Why is it important to attend?
This event will enable stakeholders to:
⢠Discuss and review existing services for warfarin monitoring; DOAC initiation and the provision of low molecular weight heparins (LMWH) dalteparin
⢠Discuss good practice and service gaps in existing services
⢠Scope options for a new integrated anticoagulation service to be delivered from April 2020
⢠Input into the design of the future commissioning model
If you would like to attend, please contact Amelia Lloyd-Hunt at …@nhs.net to register for a place.
Bids are submitted through the buyer’s own portal, not on this site. Read the full notice on Contracts Finder before relying on any date here.
No supplier information available.